Evommune (EVMN) Cash from Investing Activities (2024 - 2026)
Evommune (EVMN) reported Cash from Investing Activities of -$85.4 million for Q1 2026, down 732.29% year-over-year from $13.5 million in Q1 2025, and up 30.55% quarter-over-quarter from -$122.9 million in Q4 2025.
Evommune (EVMN) Cash from Investing Activities (2024 - 2026) Analysis & Trends
Evommune (EVMN) has 3 years of Cash from Investing Activities data on file, last reported at -$85.4 million in Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at -$85.4 million, down 732.29% year-over-year; the trailing twelve-month figure through Mar 2026 was -$227.8 million (changed N/A YoY), and the FY2025 annual result was -$115.3 million, down 2787.73% from the prior year.
- Cash from Investing Activities grew to -$85.4 million in Q1 2026 per EVMN's latest filing, from -$122.9 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $13.5 million in Q1 2025 and troughed at -$122.9 million in Q4 2025.
- A 3-year average of -$57.0 million and a median of -$59.2 million in 2024 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2025 and 2026: Cash from Investing Activities slumped 271.53% in 2025, then tumbled 732.29% in 2026.
- A 3-year view of Cash from Investing Activities shows it stood at -$33.1 million in 2024, then tumbled by 271.53% to -$122.9 million in 2025, then surged by 30.55% to -$85.4 million in 2026.
- Business Quant data shows EVMN's Cash from Investing Activities at -$85.4 million in Q1 2026, -$122.9 million in Q4 2025, and $13.5 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 579,519.10 |
| 10 | Evommune | 680.81 Mn | 469.35 Mn | - | -85.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -85.36 Mn |
| Mar 31, 2026 | -85.36 Mn |
| Dec 31, 2025 | -122.90 Mn |
| Dec 31, 2025 | -122.90 Mn |
| Mar 31, 2025 | 13.50 Mn |
| Mar 31, 2025 | 13.50 Mn |
| Dec 31, 2024 | -33.08 Mn |
| Dec 31, 2024 | -33.08 Mn |